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ABSTRACT 
 
The Effectiveness of Valdecoxib on Post-Endodontic Pain 
 
Lora Beth Ford, DDS 
 
Pain is often associated with teeth that need endodontic therapy.  This pain results 
from inflammation.  Non-Steroidal Anti-Inflammatory Drugs are useful in managing 
acute post-operative dental pain.  NSAIDS specific for only blocking the COX-2 enzyme 
cause less stomach irritation and bleeding.  The purpose of this clinical study was to 
determine if pre-operative administration of valdecoxib would significantly reduce post-
endodontic pain, when compared to ibuprofen.  Sixteen patients were evaluated.  The 
patients consented to a random, one-time, pre-operative oral administration of either 600 
mg ibuprofen or 20 mg valdecoxib.  Each patient rated their pain on a visual analog scale 
at initial, immediately after, 4, 8, 12, 24, 48, and 72 hours after initiation of endodontic 
therapy.   Statistical analysis with a two factor ANOVA showed there was no significant 
difference (p>0.05) between valdecoxib and ibuprofen at controlling post-endodontic 
pain over time.  In conclusion, valdecoxib and ibuprofen appear to have equal efficacy at 
controlling post-endodontic pain when administered pre-operatively.  
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CHAPTER I  
 
INTRODUCTION 
 
 Endodontic therapy can be a pain free experience but there are occasions when some 
discomfort can be expected.  Patients often seek treatment because they are already in pain of 
odontogenic origin.  Root canal therapy is initiated in order to reduce this pain.  When pain is 
severe before endodontic therapy, pain can also be expected to be of a moderate to severe 
intensity after therapy.(1)   
 The pain that is experienced is due to pulpal and or periapical insult which results in 
inflammation.  The inflammatory process that occurs after tissue injury is mediated by the 
breakdown of damaged cell membranes by phospholipase A2 into their fatty acid 
components.  The main fatty acid component is arachidonic acid which is then converted to 
prostaglandins, prostacyclins, and thromboxanes by various cyclooxygenase (COX) 
enzymes.  Prostaglandins are involved in hyperalgesia and inflammation.  They sensitize 
nerve endings and initiate vasodilation seen in edema.(2)   
 There are two forms of the cyclooxygenase enzyme that result in the formation of 
inflammatory products from the arachidonic acid cascade.  The first isoform is COX-1 and is 
responsible for normal homeostatic functions of prostaglandins.  Prostaglandins found in the 
gastrointestinal tract help maintain gastric mucosal integrity.  They are also found in blood 
platelets and help initiate aggregation.  Prostaglandins associated with COX-1 are normally 
found in the kidneys where they help regulate renal blood flow.(3)  COX-2 is primarily an 
inducible enzyme that is not found in most tissues under normal conditions but is produced in 
response to pain and inflammation.(4)  It is also expressed in the brain and the kidneys but its 
role there is still undefined.(5)   
 Management of pain and inflammation has been accomplished with different 
medications over the years.  Traditional Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) 
are a major drug class that have been useful in these situations and have been used in 
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managing acute post-operative dental pain.  However, many NSAIDS have undesirable side 
effects like GI irritation/toxicity, ulcers and bleeding.  These side effects could be avoided by 
using selective COX-2 inhibitors.  This newer drug class of COX-2 inhibitors has been 
shown to produce therapeutic efficacy comparable to current NSAIDS but without the GI and 
renal toxicity that contributes directly to the morbidity associated with chronic NSAID 
administration.(6)   
 Valdecoxib is a selective COX-2 inhibitor.  Studies show it has as effective or 
superior analgesic effects to traditional NSAIDS but without the associated side effects of 
nonselective NSAIDS.(7)  Also, valdexcoxib has shown a quicker onset of analgesia, 
significantly improved pain relief, and lower pain intensity when taken for post-oral surgery 
pain.(8)  If valdecoxib has comparable analgesic effects to ibuprofen for the management of 
acute pain, but without the adverse side effects, then it might be an important medication 
used in the treatment of acute pain of odontogenic origin.  The ability of valdecoxib to 
control post-endodontic pain when administered pre-operatively has not been evaluated.  The 
goal of this study is to determine if valdecoxib will significantly reduce post-endodontic pain 
when compared to ibuprofen. 
 
Significance of the study 
 
 Pain can be associated with root canal therapy before and after treatment.  This is due 
to the inflammatory process and its components.   The standard post-op medication for pain 
associated with inflammation is ibuprofen, a common NSAID.  It inhibits both COX-1 and 
COX-2 enzymes.  Valdecoxib is also an NSAID that exhibits anti-inflammatory, analgesic, 
and antipyretic properties with less gastric side effects.  It does this by selectively inhibiting 
only the COX-2 enzyme.  If valdexcoxib is more effective than ibuprofen in reducing post-
endodontic pain, with less gastric side effects, then it could be used for patients needing root 
canal therapy.   
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Statement of the problem  
 
 Is there a difference between ibuprofen and valdecoxib in controlling post endodontic 
treatment pain when administered preoperatively? 
Hypothesis 
 There is no difference between ibuprofen and valdecoxib in controlling post-
endodontic treatment pain. 
 
 
Definition of terms 
• Endodontic Pain:  Pain that a patient experiences due to inflammation and/or 
necrosis of the tooth pulp and periapical tissues. 
 
• Cyclooxygenase-1 (COX-1) enzyme:  This enzyme catalyzes the conversion of 
arachidonic acid to prostaglandin H2, the precursor of prostaglandins and 
thromboxane.  It is thought that this enzyme is found normally in the stomach, 
kidneys and platelets.  It produces prostaglandins that are beneficial to renal and 
gastric function.    
 
• Cyclooxygenase-2 (COX-2) enzyme:  This enzyme also catalyzes the conversion of 
arachidonic to prostaglandin H2.  This enzyme is normally present in the tissues in 
low levels and is associated with the mediation of inflammation and pain. It is also 
expressed in the brain and kidneys.  
 
• Valdecoxib:  An oral, nonsteroidal anti-inflammatory drug which selectively inhibits 
prostaglandin synthesis by decreasing the activity of the COX-2 enzyme, resulting in 
analgesic, antipyretic, and anti-inflammatory pharmacological effects.   
 
• Ibuprofen:  An NSAID which inhibits both COX-1 and COX-2 when controlling 
pain associated with inflammation.   
 
• Visual Analog Scale:  A 100 millimeter horizontal scale used to measure a person’s 
perception of pain.  Zero is on the extreme left and equals “no pain”, while one 
hundred is on the extreme right and equals “pain so severe you can’t stand it.” 
 
• Pulpal and Periapical Diagnoses:  These are determined for each patient by 
collecting clinical data through appropriate diagnostic tests.   
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• Acute Apical Periodontitis:  An endodontic diagnosis involving inflammation of the 
apical periodontium which produces acute symptoms of pain upon biting, percussion 
and palpation.  This is usually a result of an inflamed or dying pulp. 
 
• Phoenix Abscess:  A condition where the patient exhibits pain upon biting or 
occlusal contact, radiographically a radiolucency is located around the apex or apices 
of the root of the tooth, but there is no swelling or sinus tract. 
 
• Acute Apical Abscess:  An inflammatory reaction to pulpal infection and necrosis 
characterized by rapid onset, spontaneous pain, tenderness of the tooth to pressure, 
pus formation and swelling of associated tissues. 
 
• Chronic Apical Periodontitis:  Inflammation and destruction of the apical 
periodontium that is of pulpal origin.  Radiographically it appears as a radiolucent 
area around the roots of the tooth and does not produce any clinical symptoms. 
 
• Necrotic Pulp:  A clinical diagnosis based on subjective and objective findings that 
indicate that the pulp has undergone necrosis and death. 
 
• Irreversible Pulpitis:  Inflammation of the pulp that is severe enough that the pulp 
will not be able to recover and will eventually die.   
 
• Reversible Pulpitis:  Inflammation that is not severe enough to cause pulpal death 
and the pulp can recover if the cause of the irritation is eliminated. 
 
• Chronic Apical Abscess:  A chronic condition where there is no pain but an abscess 
or sinus tract associated with a lesion around the apices of a tooth. 
 
Assumptions 
 Pain due to inflammation is associated with endodontic therapy.  Standard non-
specific NSAIDS block both COX-1 and COX-2 enzymes which can produce unwanted side 
effects.  Patients who exhibit pain pre-operatively are likely to exhibit pain post-operatively. 
 
Limitations 
• Pre-operative and post-operative pain may differ in each patient 
 
• Valdecoxib and ibuprofen may affect patients differently 
 
• The patient must return the pain survey 
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• Endodontic diagnosis is not exact all the time 
 
• The age of the patient may cause differences in pain perception 
 
• There are gender and cultural differences among patients 
 
• Different teeth among patients will be treated 
 
• Health histories differ between patients 
 
Delimitations 
• A pulpal diagnosis of irreversible pulpitis or necrotic pulp and pain is necessary 
 
• A periapical diagnosis of acute apical periodontitis or phoenix abscess is necessary 
 
• Patients must be at least 18 years of age 
 
• Patients must not be taking antibiotics 
 
• Patients with the following conditions will not be included in the study: 
 
• Mitral Valve Prolapse 
 
• Rheumatic Heart Disease 
 
• Artificial joints or heart valves 
 
• Stroke 
 
• Untreated hypertension or hyperthyroidism 
 
• Myocardial Infarction 
 
• Hepatitis 
 
• Bleeding Disorders 
 
• Stomach ulcers 
 
• Epilepsy 
 
• Kidney problems 
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• Liver problems 
 
• Pregnant females or intending to become pregnant 
 
• Allergy or contraindication to the use of NSAIDS 
 
• Patient history of rashes 
 
• Allergy to Sulfa drugs 
 
• Alcoholism 
 
• Systemic Lupus Erythematosus 
 
• Patients taking coumadin or other anticoagulants 
 
• Patients allergic to codeine 
 
 
 
 
 
CHAPTER II 
 
LITERATURE REVIEW 
 
 
 Patients requiring endodontic therapy often have pain secondary to inflammation and 
therefore seek treatment.  Pain is not always associated with teeth in need of root canal 
therapy.  Unfortunately, it is the cases where pain is present that the public has a negative 
association with having root canal treatment.  When patients present in pain before root canal 
therapy, they will often have pain after treatment.(1)  Root canal therapy is initiated to 
remove the source of the problem and to help alleviate this discomfort.  Due to factors 
associated with inflammation and the procedure itself, total resolution of pain might not be 
possible.   
 There are different diagnoses in endodontics that can be associated with pain.  
Patients who exhibit signs of acute apical periodontitis or phoenix abscess are experiencing 
pain.  In these cases, the tooth is painful to percussion or palpation.  This discomfort is 
secondary to inflammation of the surrounding periodontal tissues of the tooth involved.   
 Even though endodontic therapy is initiated to help relieve pain, the procedure itself 
can cause some post-operative discomfort.  In a study done by Seltzer and Bender, they 
found that 40% of 698 patients experienced slight discomfort after root canal therapy.  They 
also found that patients with acute periodontitis had a higher incidence of pain that when 
compared to chronic periodontitis.  The stage of instrumentation was not related to incidence 
or duration of pain.(9)  Treatment procedures or iatrogenic factors during root canal therapy 
can lead to some post-operative discomfort.  Irrigation with 3% hydrogen peroxide and 
5.25% sodium hypochlorite, and intracanal medication between appointments with 
formocresol have a lower incidence of and degree of post-obturation pain when compared to 
teeth that are irrigated with saline and when no intracanal medication is placed between 
appointments.(10)  Teeth that have been over-instrumented beyond the apex, and sealer or 
gutta percha has been extruded out the apical area, can result in a higher incidence and 
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degree of post-obturation pain.  They also noted that post-obturation pain occurred with the 
highest incidence during the first 24 hours after treatment.(11)   
 Researchers have studied single visit endodontic treatment versus multi-visit 
treatment regarding post-operative pain.  Soltanoff compared the effects of single visit 
endodontic treatment or multiple visit treatment based on random selection of cases 
performed in clinical practice during a period of twenty years.  He found out of 135 single 
visit cases and 195 multiple visit cases, significantly more patients in the multi-visit group 
had no pain than in the single visit group.(12)  Other studies have shown the opposite effect 
though.  Roane et al. found that out of 359 cases a 2 to 1 higher frequency of pain was 
reported following multi-visit treatment compared to single visit treatment.(13)  Okeefe 
found no significant difference in post-operative pain and the number of visits.(1)  Factors 
such as pre-operative pain, treatment methods, anatomic type of tooth, and pulpal/periapical 
diagnosis could be reasons for variations in these conflicting research findings.   
 Sometimes it is not the number of visits, but the clinical diagnosis that best predicts 
pain after treatment or “flare-ups”.   Trope compared the flare-up rate for single visit root 
canal therapy among teeth with and without clinical and radiographic signs of apical 
periodontitis not previously treated and those with apical periodontitis requiring retreatment.  
He found teeth without apical periodontitis, did not flare up and could be treated in one 
appointment.  Teeth with apical periodontitis had a low flare-up rate.  Teeth with apical 
periodontitis needing retreatment had the highest flare-up rates.  He also found that thorough 
instrumentation of canals was the most important factor in decreasing the incidence of 
pain.(14)   
 Along with periapical factors as predictors of flare-ups, microorganisms should also 
be considered.  Siqueira found that certain situations during endodontic treatment facilitate 
the disruption of balance between host defenses and microbial aggression.(15)  These include 
apical extrusion of infected debris, incomplete chemo-mechanical preparation of the canals, 
and secondary infection of the canal.  Preventive measures are suggested to help minimize 
these things from occurring.  Selection of instrumentation techniques that extrude less 
amounts of debris apically, use of an antimicrobial intracanal medication between 
appointments, and not leaving the tooth open to the oral environment are a few.(16)  Balaban 
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et al. found that thorough cleansing of the canal system during the first treatment 
appointment produced no additional exacerbations and decreased treatment time.(17) 
 Pain that is associated with endodontic therapy can be attributed to the inflammatory 
response.  When a tooth requires root canal therapy there has been some form of insult or 
injury to the pulpal tissue.  This insult could be traumatic, chemical, mechanical, or bacterial. 
Whatever the cause the insult may have been, the inner network of nerves and blood vessels 
has been irreversibly affected.  A series of events takes place when this type of insult or 
injury occurs.  First, there is an increased vascular response which leads to vasodilation and 
increased vascular permeablility.  There is also release of chemical mediators such as 
histamine, serotonin, kinins, and metabolites of arachidonic acid which are prostaglandins, 
endoperoxides and prostacycline.(2)  Prostaglandins have been associated with pain.  They 
are involved in normal and pathologic processes and play important roles in inflammation.  
They are formed in response to various stimuli.  Their precursor, arachidonic acid is formed 
from the action of phospholipase A2 on membrane phospholipids.  From this point 
arachidonic acid is metabolized by two different pathways, the cyclooxygenase or 
lipoxygenase pathway.  It is from the cyclooxygenase pathway that prostaglandins are 
derived.  Prostaglandins increase vascular permeablility, induce fever, raise chemotactic 
activity and increase the sensitivity of pain receptors to other inflammatory mediators.(2)  
There are two forms of the cyclooxygenase enzyme.  One form is COX-1, which is 
responsible for normal homeostatic functions of prostaglandins in the gastrointestinal tract 
that help to maintain mucosal integrity, initiate platelet aggregation, and regulate renal blood 
flow.  COX-2 is believed to be induced during inflammation and contributes to pain, edema 
and tissue destruction.  COX-2 is found in the brain and kidneys but plays an undefined role 
in these tissues.(18) According to Torabinejad and Bakland, histamine, bradykinin, and 
prostaglandins are the most important chemical mediators of acute inflammation.(19)  
Cooper states that as these mediators build up in injured tissues, more pain impulses reach 
the central nervous system.  In the spinal column, a transmitter known as substance P is 
released and this activates the spinal pain pathways leading to the brain.(20)  Once the brain 
receives these impulses, it releases transmitters called endorphins and enkephalins to help 
relieve pain.   
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There are also exogenous ways to help alleviate this pain.  Cooper states that there are 
two major drug classes to treat pain.  The first group is peripherally acting analgesics that 
work at the site of injury.  The second group is centrally acting analgesics that work in the 
brain.(21)  The peripherally acting analgesics block the cyclooxygenase that converts 
arachidonic acid to prostaglandins.  These drugs are referred to as Non-Steroidal Anti-
Inflammatory Drugs (NSAIDS).  Cooper states that for dental pain, NSAIDS are extremely 
effective.  He also suggests that if clinically possible, pretreatment doses with these agents 
will enhance their therapeutic effect.(22)  NSAIDS like ibuprofen block the cyclooxygenase 
enzymes.  There are two isoforms of this enzyme:  COX-1 and COX-2.  This blockage 
prevents the conversion of arachidonic acid to prostaglandins.  An analgesic effect will take 
place but there are also other effects like gastrointestinal toxicity (bleeding, ulceration, and 
perforation).(23)  Some common NSAIDS include ibuprofen, naproxen, ketoprofen, 
flurbiprofen, etodolac, and ketorolac.  There have been many studies evaluating NSAIDS as 
to their efficacy at controlling orofacial pain.  Ibuprofen in doses of 200 mg-400 mg were 
demonstrated to be superior to placebo in a single dose.(24)  In a study done by Menke et al. 
they found that prophylactic ibuprofen significantly reduced post endodontic pain at 4 and 8 
hrs after initiation of root canal therapy, when compared to etodolac and a placebo.(25)  
Torabinejad et al. compared multiple medications and found that ibuprofen, ketoprofen , 
erythromycin base, penicillin and methylprednisone plus penicillin were more effective than 
placebo within the first 48 hours following complete instrumentation of canals.(26)   
Traditional NSAIDS block COX-1 and COX-2 enzymes and by doing this unwanted 
side effects can result.  This is especially true with long term use.  By inhibiting COX-1 you 
inhibit the enzyme that is responsible for producing prostaglandins with homeostatic 
functions.  For example, the prostaglandins that are responsible for gastric mucosal integrity 
and protection are blocked and gastric irritation can result.  In a study done by Langman et al. 
they looked at 1144 patients admitted to the hospital for NSAID related peptic ulcer 
bleeding.(27)  The use of NSAIDS for three months before admittance to the hospital had 
been strongly associated with these peptic ulcer bleeds.  They found that risks of this type 
increased with the dose of the NSAID.(28)  In another study, Rodriguez and Jick evaluated a 
population-based retrospective case-control study in the United Kingdom.  They assessed the 
risk of upper gastrointestinal bleeding with the use of various NSAIDS.  They found the risk 
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was greater for higher doses and azapropazone and piroxicam had the highest risk of upper 
GI bleeding.(29)  Along with gastrointestinal toxicity, other side effects are associated with 
NSAID use.  Platelet function can also be impaired because of inhibition of thromboxane, a 
potent aggregating agent.(30)  Patients on aspirin therapy for cardiovascular risks and also 
taking another NSAID such as ibuprofen or naproxen may have a decreased cardioprotective 
effect of the aspirin. 
Selective COX-2 inhibitors have an advantage over traditional NSAIDS because they 
spare the COX-1 enzyme, thus decreasing the side effects that are usually seen by inhibiting 
this enzyme.  COX-2 inhibition retains anti-inflammatory activity but decreases the risks of 
GI toxicity and bleeding.(31)  They selectively inhibit only the COX-2 isoform of the COX 
enzyme and have minimal effect on the COX-1 isoform.  The COX-2 enzyme is not found in 
platelets and therefore selective NSAIDS do not affect platelet function at usual dosages.  
Selective COX-2 inhibition may be the best choice for long term anti-inflammatory analgesia 
(greater than 3 months).(32)  Scheiman studied the gastroduodenal safety of cyclooxygenase-
2 inhibition.  He found out of 39,000 rheumatoid or osteoarthritis patients, two COX-2 
inhibitors, Celecoxib and Rofecoxib, had significantly lower rates of GI-related adverse 
events than those taking a nonselective NSAID.(33)   
Although better for GI toxicity and bleeding, COX-2 inhibitors do have some side 
effects.  Renal effects are similar to that of other NSAIDS.  Caution needs to be taken in 
patients with congestive heart failure, cirrhosis or volume depletion because it can lead to 
renal ischemia and renal insufficiency.  Cardiovascular events are also similar to that of 
traditional NSAIDS.(34)  Patients allergic to aspirin should avoid both nonselective and 
selective NSAIDS.   
Along with decreasing unwanted side effects with COX-2 inhibition, these agents are 
very effective at controlling pain.  Oral surgery models using COX-2 inhibitors have 
demonstrated their efficacy.  Malmstrom et al. studied patients that had two or more third 
molar extractions and found the analgesic effect of rofecoxib 50 mg was superior to that of 
celecoxib 200 mg and similar to ibuprofen of 400 mg.(35)  Rofecoxib also provided greater 
than 24 hours of analgesia.  Ibuprofen provided 9 hours of analgesia and celecoxib for 5 
hours.(36)  Ciconnetti et al. performed a detailed review of the literature regarding COX-2 
inhibition and post-oral surgery pain.  They found COX-2 inhibitors provided similar 
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analgesia as traditional NSAIDS but are preferable in patients taking aspirin and patients who 
are at increased risk of GI complications.  They also found that selective NSAIDS displayed 
a longer duration of analgesia than traditional NSAIDS.(37)   
Examples of specific COX-2 inhibitors are celecoxib and rofecoxib.  These are 
considered 1st generation COX-2 inhibitors.  Celecoxib was found to have a slower onset of 
action when compared to ibuprofen.(38)  Barden et al. found that a single dose of oral 
celecoxib, 200 mg, is an effective means of post-operative pain relief, similar to that of 
aspirin 600-650 mg and paracetamol 1000mg.(39)  Rofecoxib is another COX-2 inhibitor 
that has been studied in the literature.  Morrison et al. assessed the analgesic efficacy of 
rofecoxib over a 24 hour period for post-oral surgery patients.  Rofecoxib 50 mg once daily 
was as effective as ibuprofen 400 mg in the treatment of post-dental surgery pain and 
demonstrated a longer duration of action.(40)  Moore, in an unpublished thesis found there 
was no difference in controlling post-endodontic pain between rofecoxib and ibuprofen.(41)   
Valdecoxib is a newer selective COX-2 inhibitor.  It is considered a 2nd generation 
COX-2 agent.  These newer 2nd generation coxibs have a several fold higher COX-2 
selectivity than the 1st generation of coxibs.(7)  Stichtenoth and Frolich reviewed these 2nd 
generation COX-2 inhibitors and found that valdecoxib is rapidly absorbed after oral 
ingestion with a half life of 8-11 hours.  It is metabolized by the liver by the CYP450 
isoenzyme CYP3A4.  In pain control studies they found that a dose of 20-40 mg as a single 
dose or twice daily is as effective or superior to ibuprofen, diclofenac, ketorolac, rofecoxib, 
tramadol, or oxycodone/acetaminophen.(7)  Along with analgesic efficacy, they found the 
incidence of gastroduodenal ulcers in patients receiving 10-20mg of valdecoxib daily was 
significantly lower than observed with naproxen 500 mg, two times a day, and ibuprofen 800 
mg, 3 times a day.(7)  Chavez and DeKorte performed an extensive review of valdecoxib.  
Valdecoxib was approved by the FDA in November of 2001.  It has been shown to be 
effective at controlling pain and inflammation associated with rheumatoid and osteoarthritis.  
It has also shown to be effective at controlling pain associated with dysmenorrhea and post-
operative pain.(42)  As with any drug, safety and tolerance including side effects have been 
addressed with the use of valdecoxib.  There has been emphasis on cardiovascular events 
because of the potential for COX-2 inhibitors to decrease production of prostacyclin, a 
vasodilator and inhibitor of platelet aggregation.  No dose of valdecoxib was associated with 
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a significant exacerbation of existing hypertension.(43)  Chavez also found that 40 mg of 
Valdecoxib did not affect platelet aggregation or bleeding time.  GI discomfort was also 
reduced when compared to naproxen, ibuprofen, or diclofenac sodium.  They also made 
recommendations on who should avoid using COX-2 inhibitors like valdecoxib.  Patients 
with renal problems, fluid retention or heart failure, asthma, or allergy to aspirin, allergy to 
sulfa, patients with hepatic disease, or acute peptic ulcer disease should not use COX-2 
inhibitors.(44)   
When comparing valdecoxib and rofecoxib in relieving pain associated with oral 
surgery, Fricke et al. found that patients receiving valdecoxib experienced a significantly 
quicker onset of analgesia, significantly improved pain relief, and lower pain intensity 
compared with patients receiving rofecoxib.(45)  Desjardins et al. examined a single pre-
operative dose of valdecoxib at relieving post-oral surgery and bunionectomy pain.  Patients 
received a single pre-operative dose of 10 mg (oral surgery only), 20, 40, or 80 mg of 
valdecoxib.  Analgesic efficacy was assessed over 24 hour post-operative period.  They 
found that all doses of valdecoxib were well tolerated with no clinically significant treatment 
related GI, renal, or platelet adverse events.  They concluded that valdecoxib provides well 
tolerated and effective analgesia for mild to moderate post-operative pain.(46) 
COX-2 selective inhibitors are significantly more expensive than nonselective 
NSAIDS but their advantages may justify the cost.(47)  For single pre-operative dosing to 
control post-operative pain and inflammation, cost may not be a factor.   
 Evaluating and measuring pain has been examined using several different 
methods.  Scott and Huskisson found the most effective method of analyzing pain and relief 
of pain was the visual analog and graphic rating scales.(48)  Seymour found the 10 cm visual 
analog scale was more sensitive than other pain scales and could discriminate between small 
changes in pain intensity.(49) 
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CHAPTER III 
 
MATERIALS AND METHODS 
 
Sample Description 
 This study involved 19 patients who required endodontic therapy.  Each patient was 
registered and treated at West Virginia University School of Dentistry Endodontic Clinic.  
Each patient involved in the study was at least 18 years of age.  A consent form and medical 
history form was completed for every patient.  History of any of the following conditions 
excluded the patient from being involved in the study:  Mitral valve prolapse, rheumatic heart 
disease, myocardial infarction, stroke, artificial heart valves or joints, untreated hypertension, 
hyperthyroidism, hepatitis, epilepsy, bleeding disorders, kidney problems, liver problems, 
stomach ulcers, pregnancy, current use of antibiotics or pain medications, current use of any 
kind of medications contraindicated with the use of NSAIDS, allergy to sulfa drugs or history 
of allergy to NSAIDS, history of rashes, alcoholism, lupus, patients taking coumadin or other 
anticoagulant, and patients allergic to codeine.  All patients were diagnosed with pre-
operative periapical pain. They also had a pulpal diagnosis of necrotic or irreversible pulpitis.  
The patients were treated by endodontic residents at WVU SoD.  The patients were required 
to pay the WVU fee for emergency access of the tooth.  The patients were not charged for the 
medication provided and were reimbursed $15.00 for completing and returning the stamped 
pain survey. 
Research Design 
 This study assessed the ability of a pre-operative oral dose of valdecoxib to reduce 
post-endodontic pain when compared to ibuprofen.  Visual analog scales were used to collect 
data over time.  The need for additional medication was also evaluated.  The data was 
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analyzed to determine if any difference existed between valdecoxib and ibuprofen and their 
ability to decrease post-endodontic treatment pain. 
 
Clinical Exam:  Informed Consent and a medical history were obtained and a clinical exam 
was performed.  The exam included a percussion test, a cold test (endo-ice), periodontal 
probing, mobility assessment and palpation.  All signs and symptoms (past and present), 
were noted.  A pulpal and periapical diagnosis of the offending tooth was determined.  See 
flow charts (Appendix D). 
 
Visual Analog Scale:  Prior to administration of anesthetic and the medication, each patient 
recorded his/her initial pain perception on the pain survey (Appendix C).  Pain intensity was 
measured using a 100mm visual analog scale (VAS).  The scale was from zero to one 
hundred, zero was “no pain” and one hundred was “pain so severe you can’t stand it”.  The 
pain survey included a VAS for:  immediately after the root canal treatment, 4 hrs, 8 hrs, 12 
hrs, 24 hrs, 48 hrs and 72 hrs after root canal therapy was initiated.  The pain survey also 
included an area to indicate if additional medication was required at each corresponding time 
interval. 
Methodology 
 Nineteen patients were involved in this study.  The medications that were used were 
reported as safe and effective for pain and inflammation by their manufacturers.  Upon 
approval from the Institutional Review Board of West Virginia University (Appendix A), a 
consent form (Appendix B) was signed by all patients prior to treatment.  Patients consented 
to a single-blind, random, pre-operative oral administration of either 600mg ibuprofen or 20 
mg of valdecoxib.  Before anesthesia, the patient entered his/her initial pain perception on the 
pain scale. Local anesthetic was administered and endodontic access was achieved under 
rubber dam isolation.  Cleaning and shaping of the root canal system was accomplished in 
the following manner:  Negotiation of canals with Flex-o-files #8, #10, #15, #20, #25 to a 
radiographic estimate of working length.  Gates Glidden burs #2-4 were used to enlarge the 
canal orifice and irrigation with 5.25% sodium hypochlorite was used throughout the 
procedure.  Canal lubricant like RC Prep, a chelating agent, was also used on the files.  The 
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canals were dried with paper points.  Calcium hydroxide paste (Pulp Dent) was placed in 
each canal and then IRM was used as the temporary filling material.  Occlusion was 
evaluated and reduced as necessary.  Each patient was scheduled with a return appointment 
for root canal therapy completion and emergency phone numbers were given. 
 The patient then recorded his/her pain perception on the pain survey immediately 
after the procedure.  They were also instructed to do this at the 4, 8, 12, 24, 48, and 72 hour 
time intervals after root canal therapy was initiated.  A rescue medication of 5 mg 
hydrocodone/500 acetaminophen was given to each patient with the instructions to take it if 
they experience break-through pain.  They were advised to take the rescue medication only if 
needed and to record the time it was taken on the pain survey. 
Data Collection 
 The VAS values were measured with a standard millimeter ruler and recorded on the 
data collection sheet.  Additional data was also recorded on the data collection sheet like: 
Subject #, Medication #, Pulpal diagnosis, Periapical diagnosis, extra medication requirement 
and gastro-intestinal upset. 
Statistical Analysis 
 Data analysis was performed on three sets of data. The first set compared each 
medication and corresponding VAS values for each patient at each time interval.  The second 
set compared the need for extra medication with regard to pulpal and periapical diagnosis.  
The third set compared the extra rescue medication requirement with each given medication.    
The first set of data was analyzed using a two-factor ANOVA Test (P<0.05).  The second 
and third sets were analyzed using a Chi-Square Test (P<0.05). 
Equipment and Materials 
• Valdecoxib 20 mg (Pfizer Inc., New York, NY) 
• Ibuprofen 600 mg (Whitehall-Robbins, Madison, NJ) 
• Individuals receiving conventional root canal therapy 
• Local Anesthetic (Astra, Westborough, MA) 
• Flex-O-Files (Dentsply, Milford, DE) 
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• Gates-Glidden burs #2, #3, and #4 (Dentsply, Milford, DE) 
• Standard WVU School of Dentistry Endodontic set-up 
• Dental Dam (Coltene/Whaledent Inc., Mahwah, NJ) 
• 5.25% sodium hypochlorite (The Clorox Co., Oakland, CA) 
• IRM temporary material 
• Endodontic paper points (Dentsply, Milford, DE) 
•  Endo-Ice (Hygenic, Akron, OH) 
• Ektaspeed Plus dental film (Kodak, Rochester, NY) 
• Standard millimeter ruler 
• Medical history form 
• Pain survey including 10 cm (100 mm) visual analog scale 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER IV 
 
RESULTS AND DISCUSSION 
 
RESULTS 
 Nineteen subjects participated in the study.  Three subjects did not return the pain 
survey so data was analyzed for sixteen subjects. Table 1 displays the data collection sheet.   
Eight subjects received ibuprofen (six returned the survey) and eleven received valdecoxib 
(ten returned the survey).  Each subject recorded his or her perceived pain on the VAS for 
each specified time interval:  initial, immediately after, 4 hrs, 8 hrs, 12 hrs, 24 hrs, 48 hrs, 
and 72 hrs after initiation of the root canal.  Zero millimeters corresponded to “no pain” and 
100 millimeters corresponded to “pain so severe you can’t stand it” (See Appendix C).  
Seven females and twelve males were involved in the study.  The subjects who entered the 
study were not taking antibiotics or pain medications such as NSAIDS or narcotics.  Each 
subject presented with periapical pain.  Both a pulpal and a periapical diagnosis were 
determined for each subject.  Of the pulpal diagnoses, five subjects had an Irreversible 
Pulpitis and eleven had a Necrotic Pulp.  Of the periapical diagnoses, eight had Acute Apical 
Periodontitis and eight subjects had a Phoenix Abscess.  Seven subjects reported needing the 
additional pain medication following initiation of endodontic therapy. 
 Figure 1 shows comparison of each medication and its effectiveness at controlling 
pain at each time interval.  Statistical analysis showed that there was no significant difference 
between ibuprofen and valdecoxib at controlling post-endodontic pain (P-value=0.2137). 
They both reduced pain over time. Table 3 shows means and standard deviations for each 
medication at each time interval following endodontic therapy.   
 Table 4 and Figure 2 display the number of subjects who were diagnosed with each 
pulpal diagnosis.  Also displayed is the number of subjects who required additional 
medication for post-endodontic pain.  Five subjects presented with an Irreversible Pulpitis 
and one of them required extra medication for pain.  Eleven subjects presented with a 
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Necrotic Pulp and six of them required extra pain medication.  A Chi-Square analysis 
showed no significant difference between pulpal diagnosis and the need for additional 
medication (P=0.1967). 
 Table 5 and Figure 3 display the number of subjects who were diagnosed with each 
periapical diagnosis and the need for extra pain medication.  Eight subjects had Acute Apical 
Periodontitis and of those three required extra medication.  Eight subjects had Phoenix 
Abscess and four of them needed extra pain medication.  A Chi-Square analysis showed no 
significant difference between periapical diagnosis and the need for additional pain 
medication (P=0.6143). 
 Of the seven subjects who needed additional pain medication, four had received 
valdecoxib and three had received ibuprofen.  A Chi-Square analysis showed no significant 
difference between the extra medication requirement and which medication the subjects 
received (P=0.6966). 
 Of the six subjects who received ibuprofen, three needed additional medication at 
some point after initiation of root canal therapy.  Of the ten subjects who received 
valdecoxib, four required additional medication. 
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Table 1.  Data Collection Sheet 
TABLE 1 
 
Data Collection Sheet 
 
 
Pt 
# 
Med 
# Pulp Dx 
PA 
Dx 
Initi
al 
Imm 
After 
4 
Hrs 
8 
Hrs 
12 
Hrs 
24 
Hrs 
48 
Hrs 
72 
X 
Med
Hrs s GI Upset 
                            
1 b 2 1                     
2 a 2 1 28 1 1 3 2 0 1 1 0 0 
3 a 1 2 61 0 2 6 5 0 0 0 0 0 
4 b 1 2 21 0      0 0 0 0 0 0 0 0
5 a 1 2                     
6 b 1 1 66 23 26 33 65 69 9 5 1 0 
7 b 1 2 59 3 15 17 18 14 6 0 1 0 
8 b 2 1 69 0 0 0 0 0 0 0 0 0 
9 b 1 1 62 7 56 48 40 34 31 6 0 0 
10 b 1 2 80 13 32 29 0 0 5 4 9 0 
11 b 1 2 69 46 33 27 23 47 59 67 1 0 
12 b 1 2 68 6 9 8 9 11 11 0 0 7 
13 a 1 2 82 3 61 0 1 0 4 5 4 0 
14 b 2 1 62 0 19 28 0 20 26 1 0 6 
15 a 1 1 42 3 16 3 21 16 1 0 3 2 
16 a 2 1 63 6 5 5 29 24 27 22 0 0 
17 a 1 2 95 47 31 28 20 73 35 46 1 0 
18 a 2 1                     
19 b 2 1 4 5 0 0 66 4 1 16 4 0 0 
              
              
 The da  shaded in blue ere n t analyzed        ta  w o
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Table 2.  Data Collection Sheet Legend 
ABLE 2 
ata Collection Sheet Legend 
 
 
T
 
D
 
 
MED a=Ibuprofen b=valdecoxib 
Pulp Dx tic 1=Necro 2=Irrev. Pulpitis 
PA Dx 1=AAP nix abscess 2=Phoe
X-MEDS 0=No 1=Yes 
GI UPSET 0=No 1=Yes 
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FIGURE 1 
 
Experimental Medications and Pain Relief over Time  
 
 
 
Figure 1.  Experimental Medication and Pain Relief  Over Time 
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Table 3.  Means and Standard Deviations 
 
TABLE 3 
 
Means and Standard Deviations 
 
Medication Time Total Mean Standard 
        Deviation 
          
ibuprofen initial 371/6 61.83 24.7 
  immed after 60/6 10 18.2 
  4 hrs 59/6 9.83 11.7 
  8 hrs 50/6 8.33 9.7 
  12 hrs 120/6 20 22.8 
  24 hrs 103/6 17.17 28.8 
  48 hrs 84/6 14 15.6 
  72 hrs 85/6 14.17 18.2 
valdecoxib initial 622/10 62.2 15.6 
  immed after 102/10 10.2 14.5 
  4 hrs 167/10 16.7 17.7 
  8 hrs 208/10 20.8 15.6 
  12 hrs 182/10 18.2 21.7 
  24 hrs 213/10 21.3 22.5 
  48 hrs 155/10 15.5 18.4 
  72 hrs 95/10 9.5 20.6 
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Table 4.  Pulpal Diagnosis and Additional Medication 
 
TABLE 4 
 
Pulpal Diagnosis and Additional Medication 
 
Pulpal Diagnosis Subjects Extra Meds
Necrotic 11 6 
Irreversible Pulpitis 5 1 
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FIGURE 2 
 
Pulpal Diagnosis and Extra Medication 
 
Figure 2.  Pulpal Diagnosis and Extra Medication 
25 
 
Table 5.  Periapical Diagnosis and Additional Medication 
 
TABLE 5 
 
Periapical Diagnosis and Additional Medication 
 
Periapical Diagnosis Subjects Extra Meds 
Phoenix Abscess 8 4 
AAP 8 3 
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FIGURE 3 
 
Periapical Diagnosis and Extra Medication 
 
igure 3.  Periapical Diagnosis and Extra Medication F
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DISCUSSION 
 Controlling pain has been successfully managed by NSAIDS for many years.  The 
ultimate goal of these drugs is to block the cyclooxygenase enzymes that convert arachidonic 
acid to prostaglandins.(50)  It is these prostaglandins that contribute to more pain and 
inflammation.  Ibuprofen, which is the prototype of the NSAID drug class, has demonstrated 
analgesic efficacy over a range from 200-800 mg with duration of action of 4-6 hours.(51)  
NSAIDS like ibuprofen have been studied for treating pain associated with inflammation in 
endodontic applications.(41;52-54)   
 A newer class of NSAIDS, COX-2 Inhibitors, has also been studied at controlling 
acute pain.  These drugs selectively block only the COX-2 enzyme which leaves the 
protective action of prostaglandins in the stomach and kidney alone.  Valdecoxib is one of 
these drugs and has shown to be effective at controlling dental pain.(7;55-57)  Valdecoxib 
has an effective dose range of 10-80 mg with duration of action of 8-11 hours.(58)   
 In this clinical study, valdecoxib was compared to ibuprofen to evaluate its 
effectiveness at controlling post-endodontic pain.  Both ibuprofen and valdecoxib were found 
to be equally effective at controlling post-endodontic pain.  Nineteen subjects were enrolled 
in this study.  All subjects had periapical pain.  The results indicated that neither the pulpal 
nor the periapical diagnosis played a role in the need for additional pain medication.  
Approximately nine of the sixteen subjects continued to have pain over time.  This could be 
attributed to many factors.  One reason for this is that patients who have moderate to severe 
pre-operative pain are likely to have moderate to severe post-operative pain.(1;59)  The 
subjects who continued to have pain in this study all had high VAS values initially and 
continued to have pain regardless of which medication they had received.  The inflammatory 
process that is already in place does not immediately subside when root canal therapy is 
rendered.  The source of the inflammation (necrotic and or inflamed pulp tissue) has been 
removed but the inflammatory mediators take time to dissipate.  
 Another factor for continued pain reported by some subjects could be attributed to 
endodontic therapy itself.  Instrumentation of the root canal can cause post-operative pain.  
Seltzer and Naidorf stated that when endodontic therapy is performed, new irritants in the 
form of medicaments, irrigating solutions, and chemically altered tissue proteins can be 
introduced into the already inflamed tooth.(60)  They also state that changes in periapical 
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tissue pressure, microbial factors, immunological phenomena, and the nature of the 
inflammatory process alone can cause exacerbation of pain.(60)   
 Pain studies in general are difficult to measure.  Pain perception is subjective and can 
vary greatly from person to person.  Roane et al. stated that pain studies are difficult due to 
the reliability of values placed on the entity of pain.(61)  Fear plays a role in the perception 
of pain.  The fear of dentists and/or dental procedures, anxiety, apprehension, and other 
psychological factors influence the patient’s pain perception and reaction threshold.(60)  
Endodontic therapy, in particular, appears to be painful to many patients either because of 
previous experiences or from derogatory comments from others.  These induced anxieties 
intensify and perpetuate painful episodes.(60)   
 The manufacturer of valdecoxib, (Pfizer Inc.,), recommends a 40 mg dose initially to 
control acute pain and then 20-40 mg two times a day for 48 hours.   Due to inability to 
control patient adherence with this dosing schedule this was not feasible in this study.  This 
could explain why we did not see more effective pain control for valdecoxib.  Another 
possible explanation for seeing little difference in efficacy between ibuprofen and valdecoxib 
was sample size.  On April 7, 2005 the Food and Drug Administration removed valdecoxib 
from the market due to unwanted side effects shown with chronic use.  Skin and 
cardiovascular complications were cited as reasons for this removal.  We may have seen 
larger differences between ibuprofen and valdecoxib if more subjects had been involved in 
the study.   
 It has been shown that a pre-operative dose of an NSAID has been effective at 
controlling post-operative pain.(54;62-66)  This current study evaluated a one-time pre-
operative administration of either 600 mg ibuprofen or 20 mg valdecoxib and their ability to 
control post-endodontic pain.  Results showed no statistically significant differences between 
the two medications at any of the time intervals.  Of the subjects who required extra pain 
medication, the mean time to rescue medication for valdecoxib was 28 hours.  The mean time 
to rescue medication for ibuprofen was 23 hours.  Due to the longer duration of action of 
valdecoxib (8-11 hours) versus 4-6 hours for ibuprofen, these findings were perplexing.  
However, patient recording of the exact time they needed extra medication may have been 
inaccurate.  The dosing of valdecoxib in this study may also have played a role for this 
finding. 
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 The cost of valdecoxib is significantly more than for ibuprofen and would require a 
prescription.  Thirty tablets of ibuprofen (600mg) is approximately $12.49.  Thirty tablets of 
valdecoxib (20mg) is $115.27.  This averages out to $0.42 per ibuprofen tablet and $3.84 per 
valdecoxib tablet.  This is a significant cost difference and may play a role in which pain 
reliever a patient chooses to use.   
 It is interesting to note that in this study, no gastrointestinal upset was reported by any 
of the subjects for either medication at any time interval.  This is likely due to the fact that 
stomach irritation is usually associated with chronic use of NSAIDS not with single dosing.
 This study found that neither 20 mg valdecoxib nor 600 mg ibuprofen were more 
effective than the other at controlling post-endodontic pain.  Ibuprofen is a safe and effective 
drug choice to treat acute dental pain associated with inflammation.  Patients who may have a 
medical contraindication for using a traditional NSAID such as a bleeding disorder, stomach 
ulcer, or gastro-intestinal sensitivity may need a selective COX-2 inhibitor as an alternative 
choice for pain control.  Valdecoxib could have been one such choice but recent suspension 
of drug availability has eliminated this as a possible option. 
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CHAPTER V 
 
SUMMARY AND CONCLUSIONS 
 
SUMMARY 
 The purpose of this study was to compare the efficacy of pain control between 
ibuprofen and valdecoxib when administered pre-operatively.  It was hypothesized that there 
would be no difference between ibuprofen and valdecoxib in controlling post-endodontic 
treatment pain.  It was assumed that patients who were experiencing pre-operative pain were 
likely to experience post-operative pain after initiation of root canal therapy. 
 Nineteen subjects participated in this clinical study.  Each subject was diagnosed with 
periapical pain and needed root canal therapy.  They rated their pain on a pain survey 
containing a visual analog scale (VAS) and were given 600 mg ibuprofen or 20 mg 
valdecoxib before treatment was initiated.  The VAS was then taken home and subjects were 
instructed to rate their post-operative pain at the specified time intervals.  Three subjects did 
not return the pain survey so data from sixteen subjects was analyzed.   
 It was determined there was no significant difference between ibuprofen and 
valdecoxib at controlling post-endodontic pain at any of the time intervals.  They both were 
equally effective in controlling pain after root canal therapy was initiated.  There were also 
no statistically significant differences between pulpal or periapical diagnoses and the need for 
additional medication.  It was also found that a significant difference did not exist between 
the types of medication initially received and the need for additional medication.   
 This study determined that ibuprofen and valdecoxib are effective in controlling post-
endodontic pain and that neither is superior to the other when statistically compared.  
Ibuprofen is a safe and effective medication which is relatively inexpensive.  It has and will 
continue to be a common medication used for pain.  If valdecoxib were available for use it 
could be an alternative drug choice for patients unable to take traditional NSAIDS. 
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CONCLUSIONS 
 This clinical study showed no significant difference between ibuprofen and 
valdecoxib and their abilities to control post-endodontic pain when administered pre-
operatively. 
 
 
 
 
32 
 
 
 
 
REFERENCE LIST 
 
Reference List 
 
 1.  Okeefe EM. Pain in Endodontic Therapy:Preliminary Study. J.Endod. 
1976;2:315-9. 
 2.  Trowbridge H.O, Emling R. C., Inflammation.  A Review of the 
Process. 5th edition ed. Carol Stream, Illinois: Quintessence Publishing Co, Inc; 1997. 
 3.  Chavez, M. L. and DeKorte, C. J. Valdecoxib: a Review. Clin.Ther. 
2003;25(3):817-51. 
 4.  Chavez, M. L. and DeKorte, C. J. Valdecoxib: a Review. Clin.Ther. 
2003;25(3):817-51. 
 5.  Dionne, R. Pharmacologic Treatment of Acute and Chronic Orofacial 
Pain. Oral and Maxillofacial Surgery Clinics of North America 2000;12(2):309-20. 
 6.  Dionne, R. Pharmacologic Treatment of Acute and Chronic Orofacial 
Pain. Oral and Maxillofacial Surgery Clinics of North America 2000;12(2):309-20. 
 7.  Stichtenoth, D. O. and Frolich, J. C. The Second Generation of COX-2 
Inhibitors: What Advantages Do the Newest Offer? Drugs. 2003;63(1):33-45. 
 8.  Fricke, J., Varkalis, J., Zwillich, S., Adler, R., Forester, E., Recker, D. 
P., and Verburg, K. M. Valdecoxib Is More Efficacious Than Rofecoxib in Relieving Pain 
Associated With Oral Surgery. Am.J.Ther. 2002;9(2):89-97. 
 9.  SELTZER, S., BENDER, I. B., and Eherenrich, J. Incidence and 
Duration of Pain Following Endodontic Therapy. Relationship to Treatment With 
Sulfonamides and to Other Factors. Oral Surg.Oral Med.Oral Pathol. 1961;14:74-82. 
 10.  Harrison, J. W., Baumgartner, J. C., and Svec, T. A. Incidence of Pain 
Associated With Clinical Factors During and After Root Canal Therapy. Part 2. 
Postobturation Pain. J.Endod. 1983;9(10):434-8. 
 11.  Harrison, J. W., Baumgartner, J. C., and Svec, T. A. Incidence of Pain 
Associated With Clinical Factors During and After Root Canal Therapy. Part 2. 
Postobturation Pain. J.Endod. 1983;9(10):434-8. 
33 
 12.  Soltanoff, W. A Comparative Study of the Single-Visit and the 
Multiple-Visit Edodontic Procedure. J.Endod. 1978;4(9):278-81. 
 13.  Roane, J. B., Dryden, J. A., and Grimes, E. W. Incidence of 
Postoperative Pain After Single- and Multiple-Visit Endodontic Procedures. 
Oral.Surg.Oral.Med.Oral.Pathol. 1983;55(1):68-72. 
 14.  Trope, M. Flare-Up Rate of Single-Visit Endodontics. Int.Endod.J. 
1991;24(1):24-6. 
 15.  Siqueira, J. F., Jr. Microbial Causes of Endodontic Flare-Ups. 
Int.Endod.J. 2003;36(7):453-63. 
 16.  Siqueira, J. F., Jr. Microbial Causes of Endodontic Flare-Ups. 
Int.Endod.J. 2003;36(7):453-63. 
 17.  Balaban, F. S., Skidmore, A. E., and Griffin, J. A. Acute Exacerbations 
Following Initial Treatment of Necrotic Pulps. J.Endod. 1984;10(2):78-81. 
 18.  Dionne, R. Relative Efficacy of Selective COX-2 Inhibitors Compared 
With Over-the-Counter Ibuprofen. Int.J.Clin.Pract.Suppl 2003;(135):18-22. 
 19.  Torabinejad, M. and Bakland, L. K. Prostaglandins: Their Possible 
Role in the Pathogenesis of Pulpal and Periapical Diseases, Part 2. J.Endod. 1980;6(10):769-
76. 
 20.  Cooper, S. A. Treating Acute Pain: Do's and Don'Ts, Pros and Cons. 
J.Endod. 1990;16(2):85-91. 
 21.  Cooper, S. A. Treating Acute Pain: Do's and Don'Ts, Pros and Cons. 
J.Endod. 1990;16(2):85-91. 
 22.  Cooper, S. A. Treating Acute Pain: Do's and Don'Ts, Pros and Cons. 
J.Endod. 1990;16(2):85-91. 
 23.  Hutchison, R. Cox-2-Selective NSAIDS.  A Review and Comparison 
With Nonselective NSAIDS. Ameican Journal of Nursing 2004;104(3):52-5. 
 24.  Dionne, R. Pharmacologic Treatment of Acute and Chronic Orofacial 
Pain. Oral and Maxillofacial Surgery Clinics of North America 2000;12(2):309-20. 
 25.  Menke, E. R., Jackson, C. R., Bagby, M. D., and Tracy, T. S. The 
Effectiveness of Prophylactic Etodolac on Postendodontic Pain. J.Endod. 2000;26(12):712-5. 
 26.  Torabinejad, M., Cymerman, J. J., Frankson, M., Lemon, R. R., 
Maggio, J. D., and Schilder, H. Effectiveness of Various Medications on Postoperative Pain 
Following Complete Instrumentation. J.Endod. 1994;20(7):345-54. 
34 
 27.  Langman, M. J., Weil, J., Wainwright, P., Lawson, D. H., Rawlins, M. 
D., Logan, R. F., Murphy, M., Vessey, M. P., and Colin-Jones, D. G. Risks of Bleeding 
Peptic Ulcer Associated With Individual Non-Steroidal Anti-Inflammatory Drugs. Lancet. 4-
30-1994;343(8905):1075-8. 
 28.  Langman, M. J., Weil, J., Wainwright, P., Lawson, D. H., Rawlins, M. 
D., Logan, R. F., Murphy, M., Vessey, M. P., and Colin-Jones, D. G. Risks of Bleeding 
Peptic Ulcer Associated With Individual Non-Steroidal Anti-Inflammatory Drugs. Lancet. 4-
30-1994;343(8905):1075-8. 
 29.  Rodriguez, L and Jick, H. Risk of Upper Gastrointestinal Bleeding and 
Perforation Associated With Individual Non-Steroidal Anti-Inflammatory Drugs. Lancet 
1994;343:769-72. 
 30.  Hutchison, R. Cox-2-Selective NSAIDS.  A Review and Comparison 
With Nonselective NSAIDS. Ameican Journal of Nursing 2004;104(3):52-5. 
 31.  Claria, J. Cyclooxygenase-2 Biology. Curr.Pharm.Des. 
2003;9(27):2177-90. 
 32.  Hutchison, R. Cox-2-Selective NSAIDS.  A Review and Comparison 
With Nonselective NSAIDS. Ameican Journal of Nursing 2004;104(3):52-5. 
 33.  Scheiman, J. M. Gastroduodenal Safety of Cyclooxygenase-2 
Inhibitors. Curr.Pharm.Des 2003;9(27):2197-206. 
 34.  Hutchison, R. Cox-2-Selective NSAIDS.  A Review and Comparison 
With Nonselective NSAIDS. Ameican Journal of Nursing 2004;104(3):52-5. 
 35.  Malmstrom, K., Daniels, S., Kotey, P., Seidenberg, B. C., and 
Desjardins, P. J. Comparison of Rofecoxib and Celecoxib, Two Cyclooxygenase-2 
Inhibitors, in Postoperative Dental Pain: a Randomized, Placebo- and Active-Comparator-
Controlled Clinical Trial. Clin.Ther. 1999;21(10):1653-63. 
 36.  Malmstrom, K., Daniels, S., Kotey, P., Seidenberg, B. C., and 
Desjardins, P. J. Comparison of Rofecoxib and Celecoxib, Two Cyclooxygenase-2 
Inhibitors, in Postoperative Dental Pain: a Randomized, Placebo- and Active-Comparator-
Controlled Clinical Trial. Clin.Ther. 1999;21(10):1653-63. 
 37.  Cicconetti, A., Bartoli, A., Ripari, F., and Ripari, A. COX-2 Selective 
Inhibitors: a Literature Review of Analgesic Efficacy and Safety in Oral-Maxillofacial 
Surgery. Oral Surg.Oral Med.Oral Pathol.Oral Radiol.Endod. 2004;97(2):139-46. 
 38.  Dionne, R. Relative Efficacy of Selective COX-2 Inhibitors Compared 
With Over-the-Counter Ibuprofen. Int.J.Clin.Pract.Suppl 2003;(135):18-22. 
 39.  Barden J, Edwards JE McQuay HJ Moore RA. Single Dose Oral 
Celecoxib for Postoperative Pain. Cochran Databse Syst.Rev.  2003.  
35 
Ref Type: Internet Communication 
 40.  Morrison, B. W., Christensen, S., Yuan, W., Brown, J., Amlani, S., 
and Seidenberg, B. Analgesic Efficacy of the Cyclooxygenase-2-Specific Inhibitor 
Rofecoxib in Post-Dental Surgery Pain: a Randomized, Controlled Trial. Clin.Ther. 
1999;21(6):943-53. 
 41.  Moore, Stephen. The Effectiveness of Rofecoxib on Post-endodontic 
Pain.  2002.  
 42.  Chavez, M. L. and DeKorte, C. J. Valdecoxib: a Review. Clin.Ther. 
2003;25(3):817-51. 
 43.  Chavez, M. L. and DeKorte, C. J. Valdecoxib: a Review. Clin.Ther. 
2003;25(3):817-51. 
 44.  Chavez, M. L. and DeKorte, C. J. Valdecoxib: a Review. Clin.Ther. 
2003;25(3):817-51. 
 45.  Fricke, J., Varkalis, J., Zwillich, S., Adler, R., Forester, E., Recker, D. 
P., and Verburg, K. M. Valdecoxib Is More Efficacious Than Rofecoxib in Relieving Pain 
Associated With Oral Surgery. Am.J.Ther. 2002;9(2):89-97. 
 46.  Desjardins, P. J., Shu, V. S., Recker, D. P., Verburg, K. M., and 
Woolf, C. J. A Single Preoperative Oral Dose of Valdecoxib, a New Cyclooxygenase-2 
Specific Inhibitor, Relieves Post-Oral Surgery or Bunionectomy Pain. Anesthesiology 
2002;97(3):565-73. 
 47.  Hutchison, R. Cox-2-Selective NSAIDS.  A Review and Comparison 
With Nonselective NSAIDS. Ameican Journal of Nursing 2004;104(3):52-5. 
 48.  Scott, J and Huskisson, E. C. Graphic Representation of Pain. Pain 
1976;2:175-84. 
 49.  Seymour, R. A. The Use of Pain Scales in Assessing the Efficacy of 
Analgesics in Post-Operative Dental Pain. Eur.J.Clin.Pharmacol. 1982;23(5):441-4. 
 50.  Cooper, S. A. Treating Acute Pain: Do's and Don'Ts, Pros and Cons. 
J.Endod. 1990;16(2):85-91. 
 51.  Dionne, R. Relative Efficacy of Selective COX-2 Inhibitors Compared 
With Over-the-Counter Ibuprofen. Int.J.Clin.Pract.Suppl 2003;(135):18-22. 
 52.  Menke, E. R., Jackson, C. R., Bagby, M. D., and Tracy, T. S. The 
Effectiveness of Prophylactic Etodolac on Postendodontic Pain. J.Endod. 2000;26(12):712-5. 
36 
 53.  Torabinejad, M., Cymerman, J. J., Frankson, M., Lemon, R. R., 
Maggio, J. D., and Schilder, H. Effectiveness of Various Medications on Postoperative Pain 
Following Complete Instrumentation. J.Endod. 1994;20(7):345-54. 
 54.  Flath R.K, Hicks, M. L., Dionne, R, and Pelleu, G. B. Pain Supression 
After Pulpectomy With Pre-Operative Flurbiprofen. J.Endod. 1987;13:339-47. 
 55.  Fricke, J., Varkalis, J., Zwillich, S., Adler, R., Forester, E., Recker, D. 
P., and Verburg, K. M. Valdecoxib Is More Efficacious Than Rofecoxib in Relieving Pain 
Associated With Oral Surgery. Am.J.Ther. 2002;9(2):89-97. 
 56.  Cicconetti, A., Bartoli, A., Ripari, F., and Ripari, A. COX-2 Selective 
Inhibitors: a Literature Review of Analgesic Efficacy and Safety in Oral-Maxillofacial 
Surgery. Oral Surg.Oral Med.Oral Pathol.Oral Radiol.Endod. 2004;97(2):139-46. 
 57.  Desjardins, P. J., Shu, V. S., Recker, D. P., Verburg, K. M., and 
Woolf, C. J. A Single Preoperative Oral Dose of Valdecoxib, a New Cyclooxygenase-2 
Specific Inhibitor, Relieves Post-Oral Surgery or Bunionectomy Pain. Anesthesiology 
2002;97(3):565-73. 
 58.  Desjardins, P. J., Shu, V. S., Recker, D. P., Verburg, K. M., and 
Woolf, C. J. A Single Preoperative Oral Dose of Valdecoxib, a New Cyclooxygenase-2 
Specific Inhibitor, Relieves Post-Oral Surgery or Bunionectomy Pain. Anesthesiology 
2002;97(3):565-73. 
 59.  Torabinejad, M., Cymerman, J. J., Frankson, M., Lemon, R. R., 
Maggio, J. D., and Schilder, H. Effectiveness of Various Medications on Postoperative Pain 
Following Complete Instrumentation. J.Endod. 1994;20(7):345-54. 
 60.  Seltzer.S. and Naidorf, I. Flare-Ups in Endodontics 1. Etiological 
Factors. J.Endod. 2004;30:476-81. 
 61.  Roane, J. B., Dryden, J. A., and Grimes, E. W. Incidence of 
Postoperative Pain After Single- and Multiple-Visit Endodontic Procedures. 
Oral.Surg.Oral.Med.Oral.Pathol. 1983;55(1):68-72. 
 62.  Menke, E. R., Jackson, C. R., Bagby, M. D., and Tracy, T. S. The 
Effectiveness of Prophylactic Etodolac on Postendodontic Pain. J.Endod. 2000;26(12):712-5. 
 63.  Cooper, S. A. Treating Acute Pain: Do's and Don'Ts, Pros and Cons. 
J.Endod. 1990;16(2):85-91. 
 64.  Desjardins, P. J., Shu, V. S., Recker, D. P., Verburg, K. M., and 
Woolf, C. J. A Single Preoperative Oral Dose of Valdecoxib, a New Cyclooxygenase-2 
Specific Inhibitor, Relieves Post-Oral Surgery or Bunionectomy Pain. Anesthesiology 
2002;97(3):565-73. 
37 
 65.  Dionne, R. Relative Efficacy of Selective COX-2 Inhibitors Compared 
With Over-the-Counter Ibuprofen. Int.J.Clin.Pract.Suppl 2003;(135):18-22. 
 66.  Dionne, R, Campbell, R. A., Cooper, S. A., Hall, D. L., and 
Buckingam, B. Supression of Post-Operative Pain by the Pre-Operative Administration of 
Ibuprofen in Comparison to Placebo, Acetaminophen, and Acetaminophen Plus Codeine. 
J.Clin.Pharmacol 1983;23:37-43. 
 
 
 
 
 
 
 
 
 
38 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPPENDIX A 
 
IRB PROTOCOL APPROVAL 
 
 
 
39 
 40 
 
 
 
 
 
 
41 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPPENDIX B 
 
PATIENT CONSENT FORM 
IRB PROTOCOL STATEMENT 
 
42 
 
 
 
43 
44 
45 
46 
47 
 
 
 
 
48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
50 
 51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX C 
 
 
PAIN SURVEY 
 
52 
53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX D 
 
PULPAL AND PERIAPICAL DIAGNOSIS FLOW CHARTS 
 
 
54 
55 
56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX E 
 
MEDICATION SCHEDULE 
 
 
57 
 
   Randomization of Medication Dispersion 
    
 Subject Med  
 1 b  
 2 a  
 3 a  
 4 b  
 5 a  
 6 b  
 7 b  
 8 b  
 9 b  
 10 b  
 11 b  
 12 b  
 13 a  
 14 b  
 15 a  
 16 a  
 17 a  
 18 a  
 19 b  
 
 
58 
 
 
 
 
 
 
CURRICULUM VITAE 
 
Lora Beth Ford DDS, MS 
 June 5, 1976 
Honolulu, Hawaii 
EDUCATION 
 
West Virginia University M.S.                        2003-2005 
    Certificate in  
    Endodontics 
 
West Virginia University D.D.S.                        1999-2003 
 
West Virginia University B.S.D.H.                       1995-1999 
 
PROFESSIONAL ORGANIZATIONS 
 
American Association of Endodontists                       2003-present 
American Dental Association         1999-present 
Psi Omega Dental Fraternity         2000-2003 
 Secretary          2000-2001 
Student American Dental Hygienists         1995-1999 
 Association 
 President          1998-1999 
 Secretary          1997-1998 
 
AWARDS
 
Omicron Kappa Upsilon National Dental       2003 
 Honor Society     
American Academy of Oral and                     2003 
 Maxillofacial Surgery Pathology 
 Award 
WVU Local Anesthesia Award                     2003 
West Virginia Dental Scholarship                      2001-2003  
Thomas P. Hinman Dental Society  
 Scholarship                      2002 
Kanawha Valley Dental Society Scholarship                    2002 
Pierre Fauchard Academy Scholarship                     2002 
WVU Alumni Association Award for  
 Outstanding Clinical Competency 
              and Professionalism                    1999 
Sigma Phi Alpha National Dental Hygiene 
 Honor Society                     1999 
 
 
 
59 
